MECOM and breast cancer: Indeed, when we analyzed 1459 ER+ breast cancer patients in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) database (Curtis et al. 2012), we observed that higher MECOM gene expression was associated with worse hazard ratio (HR) in terms of overall survival (OS) (HR = 2.27, P-value = .048) and relapse-free survival (RFS) (HR = 3.34, P-value = .015).